|Toxiciy Grade:||4||City/State/Province:||New York, N.Y.|
|Treatments:||Biologic therapy||Hospital:||Weill Medical College of Cornell University|
Patients: This Phase I study involved 35 men with hormone-refractory protstate cancer. The median age was 69 years.
Treatment: The treatment consisted of one biological agent: J591, an isotope-labeled monoclonal antibody that recognizes the prostate specific antigen that is expressed in tumor cells.
Toxicity: Grade 3-4 toxicities included neutropenia, thrombocytopenia, and elevated liver enzymes.
Results: The median overall survival was not reported. The authors were encouraged with the antibody's relatively low toxicity and ability to target tumor tissue.
Correspondence: Neil H. Bander, M.D.